KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Long-Term Investments (2019 - 2025)

Historic Long-Term Investments for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $419.0 million.

  • Royalty Pharma's Long-Term Investments fell 3958.18% to $419.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $419.0 million, marking a year-over-year decrease of 3958.18%. This contributed to the annual value of $419.0 million for FY2025, which is 3958.18% down from last year.
  • According to the latest figures from Q4 2025, Royalty Pharma's Long-Term Investments is $419.0 million, which was down 3958.18% from $302.5 million recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's Long-Term Investments ranged from a high of $693.5 million in Q4 2024 and a low of $275.9 million during Q2 2025
  • Over the past 5 years, Royalty Pharma's median Long-Term Investments value was $418.6 million (recorded in 2022), while the average stood at $441.4 million.
  • Per our database at Business Quant, Royalty Pharma's Long-Term Investments surged by 7375.51% in 2024 and then crashed by 5619.72% in 2025.
  • Quarter analysis of 5 years shows Royalty Pharma's Long-Term Investments stood at $435.4 million in 2021, then dropped by 8.78% to $397.2 million in 2022, then rose by 10.05% to $437.1 million in 2023, then soared by 58.66% to $693.5 million in 2024, then plummeted by 39.58% to $419.0 million in 2025.
  • Its last three reported values are $419.0 million in Q4 2025, $302.5 million for Q3 2025, and $275.9 million during Q2 2025.